Exzeo Group, Inc.
XZO NYSE Services-Prepackaged Software Financials FY2023βFY2025
What Exzeo Group, Inc. does
No business description yet.
- Legal name
- Exzeo Group, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 26, 2026
- Accession Β· CIK
- 0001193125-26-076686
0001873951
Revenue and margins
Exzeo Group, Inc. had $217M of revenue in fiscal 2025, up 62.0% on the year before.
Net income and earnings per share
From fiscal 2023 to 2025, diluted EPS grew 156.9% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $97.5M in fiscal 2025, 44.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Exzeo Group, Inc. returned $1.5M to shareholders in fiscal 2025, 2% of free cash flow. The diluted share count rose 3.5%.
Balance sheet
Cash, debt and the ratios that show how comfortably Exzeo Group, Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $15.1M | $54.5M | $305M |
| Current ratio | β | 1.2x | 3.9x |
| Quick ratio | β | 1.2x | 3.9x |
| Total assets | β | $89.4M | $348M |
| Total liabilities | β | $73.9M | $93.6M |
| Shareholders' equity | β$25.3M | $15.5M | $254M |
| Net debt (β = net cash) | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 5 | 5 / 8 |
| Accruals ratio | β | β4.4% | β8.0% |
| Altman Z'' | β | 1.78 | 9.69 |
3 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $88.3M | $134M | $217M |
| Gross profit | $17.3M | $53.2M | $131M |
| Research and development | $6.5M | $6.5M | $8.8M |
| Operating income | $2.6M | $38.0M | $106M |
| Pretax income | $0.9M | $35.2M | $110M |
| Income tax | β$12.0M | $9.2M | $27.5M |
| Net income | $21.5M | $45.3M | $82.7M |
| Net income to common | $12.1M | $35.2M | $82.7M |
| Diluted EPS | $0.15 | $0.44 | $0.99 |
| Diluted shares | 0.08B | 0.08B | 0.08B |
| Cash flow | |||
| Cash from operations | $10.2M | $49.3M | $100M |
| Capital expenditure | $3.2M | $3.3M | $2.8M |
| Free cash flow | $6.9M | $45.9M | $97.5M |
| Depreciation and amortization | $1.9M | $2.2M | $2.4M |
| Stock-based compensation | $2.9M | $3.4M | $2.6M |
| Share buybacks | $0.4M | $0.5M | $1.5M |
| Dividends and buybacks | $0.4M | $0.5M | $1.5M |
| Balance sheet | |||
| Cash and short-term investments | $15.1M | $54.5M | $305M |
| Current assets | β | $67.2M | $326M |
| Current liabilities | β | $56.4M | $84.4M |
| Property and equipment, net | β | $10.8M | $10.7M |
| Total assets | β | $89.4M | $348M |
| Total liabilities | β | $73.9M | $93.6M |
| Shareholders' equity | β$25.3M | $15.5M | $254M |
| Margins | |||
| Gross margin | 19.6% | 39.7% | 60.4% |
| Operating margin | 2.9% | 28.4% | 48.8% |
| EBITDA margin | 5.0% | 30.0% | 50.0% |
| Net margin | 24.3% | 33.8% | 38.1% |
| FCF margin | 7.8% | 34.3% | 44.9% |
| Returns | |||
| Return on capital employed | β | 115.0% | 40.2% |
| Return on equity | β | β | 61.4% |
| Return on assets | β | 50.7% | 37.9% |
| Return on tangible equity | β | 226.8% | 32.6% |
| Growth | |||
| Revenue growth | β | 51.6% | 62.0% |
| Net income growth | β | 111.2% | 82.6% |
| EPS growth | β | 193.3% | 125.0% |
| FCF growth | β | 565.1% | 112.2% |
| Share count change | β | 1.8% | 3.5% |
| Financial health | |||
| Current ratio | β | 1.2x | 3.9x |
| Quick ratio | β | 1.2x | 3.9x |
| Capital allocation | |||
| Capex / revenue | 3.7% | 2.5% | 1.3% |
| Stock comp / revenue | 3.3% | 2.5% | 1.2% |
| Payouts / FCF | 5.1% | 1.0% | 1.5% |
| Quality scores | |||
| Piotroski F-score | β | β | 5.0 |
| Altman Z'' | β | 1.8 | 9.7 |
| Accruals ratio | β | β4.4% | β8.0% |
Source: SEC EDGAR XBRL filings (CIK 0001873951). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.